Drug Profile
Research programme: cancer therapeutics - PYC Therapeutics
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Phoremost; Phylogica
- Class
- Mechanism of Action Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer